TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03379727
Drug: anthracycline ((daunorubicin or idarubicin): Induction Phase only
Approvals — FDA: no, EMA: no, PMDA: no
Description: daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
Study: NCT02644668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granules for oral suspension (placebo)
Study: NCT03126968
Drug: Topical epinephrine
Normalized name: epinephrine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic topical epinephrine
Study: NCT03126968
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo (normal saline)
Study: NCT02547220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 7 doses of matched placebo over 13 days of treatment.
Study: NCT01188031
Drug: NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
Study: NCT04033861
Drug: rhBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
Study: NCT00655408
Drug: elemental iron
Normalized name: Elemental Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation.
Study: NCT01730053
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin over-encapsulated tablets orally.
Study: NCT01730053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for alirocumab and ezetimibe.
Study: NCT01663961
Drug: YM178 OCAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00382200
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03192488
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin placebo
Study: NCT00209261
Drug: MINIRIN Oral Lyophilisate
Normalized name: Miniprin Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005791
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00360685
Drug: Tac+MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
Study: NCT01660750
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO on days 1, 8, and 15 every 28 days
Study: NCT00901550
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
Study: NCT00118339
Drug: chemoprotection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02512302
Drug: Seebri® Breezhaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Study: NCT01100086
Drug: Reformulated OXY (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 10-mg tablet x 1 dose taken without food
Study: NCT01100086
Drug: Original OxyContin® (OXY) (oxycodone HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
Study: NCT00683618
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule/Tablet, oral, qd, 6 or 12 weeks
Study: NCT00730483
Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02844933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral solution
Study: NCT02984865
Drug: Sulfentanyl
Normalized name: Sufentanyl
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02984865
Drug: flubiprofen axetil
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02004366
Drug: Basal Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
Study: NCT01479465
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours
Study: NCT01479465
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours
Study: NCT01822639
Drug: GSK2944404 FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
Study: NCT02225639
Drug: PRC-063 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25 mg capsule - active
Study: NCT02225639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule
Study: NCT02225639
Drug: PRC-063 35 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 35 mg capsule - active
Study: NCT02225639
Drug: PRC-063 45 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 45 mg capsule - active
Study: NCT02225639
Drug: PRC-063 55 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 55 mg capsule - active
Study: NCT02225639
Drug: PRC-063 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 100 mg capsule - active
Study: NCT02826486
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: • IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
Study: NCT01760304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated.
Study: NCT03168711
Drug: Inosine
Normalized name: Inosine
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
Study: NCT03168711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
Study: NCT02861105
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
Study: NCT03136237
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 of Cohort 2
Study: NCT02110303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet (identical to ticagrelor), twice daily, 12 month duration
Study: NCT00314340
Drug: hydrocodone plus acetaminophen
Normalized name: acetaminophen / hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00314340
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02139098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02894645
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02894645
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal/ Intravenous/ Oral
Study: NCT02894645
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT02894645
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT00857675
Drug: AAAA
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'AAAA'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
Study: NCT01585415
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT00865228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
Study: NCT00449865
Drug: creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo.
Study: NCT02626026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally.
Study: NCT02356588
Drug: Sufentanil Tablet 30 mcg
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02356588
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01507792
Drug: iron sulphate
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 or 2 330 mg/daily iron sulphate oral tablets
Study: NCT02479451
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study medication will be provided by Foundation Care.
Study: NCT04018131
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT00381862
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: as per institutional standard of care
Study: NCT00381862
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: as per institutional standard of care
Study: NCT00375973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill dose comparable to duloxetine
Study: NCT00891020
Drug: Nonbiologic DMARDs of investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
Study: NCT01691560
Drug: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Study: NCT01691560
Drug: 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Study: NCT01544985
Drug: placebo po
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile water
Study: NCT03574285
Drug: Anpl-one SR Tab. 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
Study: NCT03574285
Drug: Sarpodipil SR Tab. 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
Study: NCT04297748
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
Study: NCT04557215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
Study: NCT02087540
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02087540
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02087540
Drug: Placebo(for Rosuvastatin 20mg)
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02087540
Drug: Placebo(for Rosuvastatin 10mg)
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05863260
Drug: Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group
Study: NCT00326274
Drug: Helioblock® SX Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03038867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
Study: NCT00427648
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT04351919
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg per day during 5 days
Study: NCT02182115
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
Study: NCT00380133
Drug: SB681323
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
Study: NCT00380133
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
Study: NCT00380133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets matched to SB681323 or prednisolone
Study: NCT04282941
Drug: Ibuprofen in continuous (24 hours) iv infusion and EchoG
Normalized name: hydrocodone and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
Study: NCT04282941
Drug: IV bolus Ibuprofen slow (15 minutes) and EchoG
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
Study: NCT04415164
Drug: Xueshuantong lyophilized powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
Study: NCT04415164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
Study: NCT02637206
Drug: GSK2894512 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
Study: NCT02637206
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
Study: NCT02637206
Drug: Empty Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty patches without any ingredients will be used as negative control.
Study: NCT02045069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 3 days
Study: NCT02824055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
Study: NCT02824055
Drug: RO5545965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
Study: NCT00348777
Drug: thermal cure
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
Study: NCT03019237
Drug: anti-IgE
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal anti-IgE
Study: NCT02174510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00372008
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003835
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00003835
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03059017
Drug: Niosomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niosomes
Study: NCT02220738
Drug: ABT-957
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-957 administered twice-daily for 7 days
Study: NCT00131612
Drug: FEC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
Study: NCT00030901
Drug: L-selenomethionine
Normalized name: L-Selenomethionine Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization between active L-selenomethionine and placebo
Study: NCT00030901
Drug: L-selenomethionine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization between active L-selenomethionine and placebo
Study: NCT03102996
Drug: Nephrotrans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hydrogen carbonate, ATC-Code: A02AH
Study: NCT02418182
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen total dose of 1000mg
Study: NCT02418182
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects randomized to this group will be given placebo tablets
Study: NCT00764660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00925951
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
Study: NCT03821454
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
Study: NCT03821454
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
Study: NCT02612623
Drug: Placebo (for gefapixant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
Study: NCT00191477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
Study: NCT01218880
Drug: M2ES 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2ES Dosage：7.5mg/m2
Study: NCT01218880
Drug: M2ES 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2ES Dosage：15mg/m2
Study: NCT01593644
Drug: adenosine + dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
Study: NCT00090025
Drug: 5-Fluorouracil Plus Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
Study: NCT00630825
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00630825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01228734
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study: NCT02042014
Drug: QTI571
Approvals — FDA: no, EMA: no, PMDA: no
Description: QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
Study: NCT02478424
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes